Mucopolysaccharidosis (MPS): cross-border access to US specialty therapies for international patients
Metabolic / lysosomal storage · specialty and rare-disease access
ICD-10: E76
About mucopolysaccharidosis (MPS)
Mucopolysaccharidosis (MPS) is a group of lysosomal storage disorders caused by defects in the metabolism of glycosaminoglycans (GAGs). FDA-approved enzyme replacement therapies (ERTs) include Aldurazyme (laronidase) for MPS I, Elaprase (idursulfase) for MPS II (Hunter syndrome), Vimizim (elosulfase alfa) for MPS IVA (Morquio A syndrome), Naglazyme (galsulfase) for MPS VI (Maroteaux-Lamy syndrome), and Mepsevii (vestronidase alfa) for MPS VII (Sly syndrome).
Why specialty drugs for MPS are hard to access internationally
MPS enzyme replacement therapies are high-cost biologics with narrow patient populations. National registration is inconsistent across markets, and even where registered, reimbursement is often partial or limited to specific MPS subtypes. Families frequently confront a registered ERT for one subtype but not the one their child actually has.
Access to specialty treatment
Patients with mucopolysaccharidosis who live in countries where their prescribed enzyme replacement therapy is not registered or is not covered by insurance can consider Named Patient Program (NPP) access. Reserve Meds coordinates this pathway: we work with your treating physician, support destination-country documentation (for example CDSCO in India, MoHAP in the UAE, SFDA in Saudi Arabia), and source the medicine from DSCSA-compliant US wholesalers under validated cold-chain shipment.
Cross-border pathways used for MPS
Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:
What your physician needs to know
- Enzyme-assay or genetic confirmation of the MPS subtype.
- Neurological versus somatic-only disease profile (relevant to ERT response).
- HSCT considerations versus ERT for eligible MPS I patients.
- Which documents the destination country requires for rare-disease enzyme replacement therapy.
Where Reserve Meds fits in
Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For mucopolysaccharidosis, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain shipment to the destination country.
We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.
Start a request
Request a drug for mucopolysaccharidosis
Reserved for you.